Weight Loss Injections (2026): Every FDA-Approved Option
Five FDA-approved injectable medications can produce meaningful weight loss in 2026. Three (Wegovy, Zepbound, Saxenda) are FDA-approved specifically for chronic weight management. Two (Ozempic, Mounjaro) are FDA-approved for type 2 diabetes but commonly prescribed off-label for weight loss. Below: side-by-side comparison, how they work, what they cost, and where to get them.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
About this page
Every drug listed below is FDA-approved with a published label on DailyMed (NIH). Mechanism, indication, administration route, dosing, and approval-date data are pulled from our primary-source-verified drug database. Cost data was verified live on 2026-05-09 from manufacturer self-pay portals (NovoCare, LillyDirect), retailer programs (Costco Member Prescription Program via Sesame, Sam's Club Plus, Amazon Pharmacy), and GoodRx. We do not paraphrase indication language.
What are weight loss injections?
All five FDA-approved weight loss injections currently on the US market are GLP-1 receptor agonists (one is also a GIP/GLP-1 dual agonist). They are self-administered subcutaneous injections — a small needle into the fat layer of the abdomen, thigh, or back of the upper arm — and they reduce appetite via the GLP-1 signaling pathway plus slow gastric emptying. Three are FDA-approved for chronic weight management; two are FDA-approved for type 2 diabetes and prescribed off-label for weight loss when the weight-loss-indicated drugs are unavailable, denied by insurance, or contraindicated. The class history started with Byetta (exenatide) in 2005 for type 2 diabetes; Saxenda was the first weight-management indication in December 2014; Wegovy, Zepbound, and Foundayo followed.
For the deeper biology of GLP-1 — what the hormone is, how the receptor works, and the four physiologic actions (insulin secretion, glucagon suppression, gastric emptying, central appetite suppression) — see our GLP-1 complete guide. For oral weight loss medications (Foundayo, Rybelsus, Qsymia, Contrave, Xenical), see our FDA-approved weight loss medications hub (which compares pills vs injections side-by-side).
Every FDA-approved weight loss injection, compared
All five injections side-by-side. Pivotal trial efficacy cited from the canonical phase 3 publication for each drug; full PMID citations live in our bariatric vs GLP-1 decision guide.
| Brand | Generic | Indication | Guide |
|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | Weight management; CV risk reduction | Wegovy → |
| Zepbound | Tirzepatide | Weight management; OSA in obesity | Zepbound → |
| Saxenda | Liraglutide 3 mg | Chronic weight management | DailyMed → |
| Ozempic | Semaglutide (lower-dose) | Type 2 diabetes (off-label for weight loss) | Ozempic → |
| Mounjaro | Tirzepatide | Type 2 diabetes (off-label for weight loss) | Mounjaro → |
What weight loss injections cost in 2026
Brand-name injection list prices range widely depending on channel. Verified live 2026-05-09 from manufacturer + retailer primary sources:
Wegovy (semaglutide)
- NovoCare self-pay: $299/month (standard pen, all doses 0.25–2.4 mg)
- NovoCare HD pen 7.2 mg: $399/month
- Wegovy oral pill 1.5/4 mg: $149/month
- Costco CMPP via Sesame: $349/month (new pt $199 × 2 mo)
- Sam's Club: $499/month via copay program
- With insurance copay savings card: as little as $25/month
Zepbound (tirzepatide)
- LillyDirect vials self-pay (effective Dec 1, 2025): $299 / $399 / $449 by strength
- LillyDirect KwikPen self-pay: $299–$699 by strength
- Sam's Club KwikPen: $299/$399/$499/$699
- GoodRx coupon path: $299/month (manufacturer-funded)
Saxenda (liraglutide)
- Brand list: ~$1,300/month
- Generic liraglutide (Teva, launched Aug 28 2025): pricing varies by pharmacy
- Manufacturer copay savings card: as little as $25/month for commercially insured
Ozempic (off-label) + Mounjaro (off-label)
- Ozempic NovoCare new patient: $199/mo for first 2 months; $349 standard
- Ozempic GoodRx: $149/month (oral 1.5 mg) / pen via Novo
- Mounjaro: no DTC self-pay program; copay savings card for commercial
- Off-label use is rarely insurance-covered for weight loss when the patient does not have type 2 diabetes
For the live channel-by-channel pricing index across every channel + compounded options ($99–$400/mo), see our GLP-1 pricing index. Brand and compounded GLP-1s are generally HSA/FSA-eligible with a prescription per IRS Publication 502.
How to get a weight loss injection (telehealth, retail, insurance)
Three primary channels:
- Insurance + traditional prescriber. Your PCP or an obesity-medicine specialist writes the prescription, your pharmacy fills it, your insurance applies the prior-authorization criteria. See our Cigna PA guide and Aetna PA guide for verbatim payer policy. The Cigna 11-condition comorbidity list, the Aetna 6-month behavioral-program requirement, and the CVS Caremark July 2025 Wegovy- preferred swap are the three things most prescribers under-document.
- GLP-1 telehealth providers. Online clinic + 503A pharmacy partnership. Cash-pay compounded semaglutide / tirzepatide typically $99–$400/ month. See our best semaglutide providers and best tirzepatide providers for ranked options. Note: the FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025 — the regulatory landscape is unsettled.
- Direct-to-consumer manufacturer pharmacies. NovoCare (Wegovy/Ozempic), LillyDirect (Zepbound/ Mounjaro/Foundayo), Costco CMPP via Sesame partner, Sam's Club Plus, Amazon Pharmacy. Cash-pay only — not eligible for insurance.
Once you have the medication, follow the FDA-label injection technique. See our step-by-step injection technique guide for every common pen and vial format, including the three FDA-approved injection sites (abdomen, thigh, back of upper arm), needle gauge, depth, angle, and the site-rotation schedule that minimizes lipohypertrophy.